Sanuwave Health, INC 8-K filings

SANUWAVE Health reports preliminary Q4 2024 revenue between $10.1 million and $10.3 million, marking the highest quarterly revenue in the company's history.

Sanuwave Health, Inc. reports the departure of its Executive Vice President of Sales, Timothy Hendricks, and the appointment of Timothy Wern as his successor.

SANUWAVE Health announces the resignation of director Kevin A. Richardson, II, along with the full vesting of his stock options.

SANUWAVE Health reports record Q3 2024 revenue of $9.4 million, a significant 89% increase year-over-year, and achieves operating income positivity.

SANUWAVE Health, Inc. has granted stock options to several current and former executive officers under its 2024 Equity Incentive Plan.

Sanuwave Health executed a reverse stock split, exchanged convertible notes and warrants, and closed a $10.3 million private placement to improve its financial position.

SANUWAVE Health reported record quarterly revenues of $7.2 million for Q2 2024, a 53% increase compared to the same period last year.

SANUWAVE Health, Inc. stockholders approved a new equity incentive plan and a reverse stock split, as detailed in a recent 8-K filing.

Sanuwave Health has entered into a sixth amendment to its debt agreement, securing further forbearance from noteholders until December 31, 2024, while also adding a consent fee and adjusting interest calculations.

SANUWAVE Health reports preliminary second-quarter revenue between $7.0 and $7.2 million, marking the highest quarterly revenue in the company's history.

Sanuwave Health has terminated its merger agreement with SEP Acquisition Corp. and will explore other options for capital structure improvement, including a reverse stock split and note and warrant exchanges.

Sanuwave Health, Inc. secures $1.8 million through a private placement involving convertible notes and warrants, alongside a separate promissory note.

Sanuwave Health has settled a significant debt, changed its exchange listing application from Nasdaq to Cboe BZX, and extended its merger deadline with SEPA.

Sanuwave Health and SEP Acquisition Corp. have extended the deadline for their merger agreement to June 30, 2024, and Sanuwave now has the unilateral right to terminate the agreement.

Sanuwave Health announced a 53% increase in revenue for Q1 2024 compared to Q1 2023, driven by strong sales of UltraMist consumables and systems.

Sanuwave Health and SEP Acquisition Corp. have extended the deadline for their merger agreement to May 31, 2024.

SANUWAVE Health reports preliminary Q1 2024 revenue between $5.7 and $5.9 million, marking the highest Q1 revenue in company history and a 51-56% increase year-over-year.

SANUWAVE Health has appointed Peter Sorensen as its new Chief Financial Officer, effective April 1, 2024, following the termination of Toni Rinow.

SANUWAVE Health announced record revenue for both the fourth quarter and full year 2023, alongside a significant improvement in operating income and provided strong revenue growth guidance for 2024.

Sanuwave Health has entered into a licensing agreement for its intravascular shockwave patents, receiving $2.5 million upfront and amending its debt agreement to release the patents from collateral.

Sanuwave Health and SEP Acquisition Corp. have amended their merger agreement, extending the deadline for completion to April 30, 2024.

Sanuwave Health, Inc. stockholders have approved the merger with SEP Acquisition Corp., paving the way for the company to become a subsidiary of SEPA.

Sanuwave Health, Inc. has entered into a securities purchase agreement for $4.6 million in convertible notes and warrants, coinciding with a planned business combination with SEP Acquisition Corp.